PTGX PROTAGONIST THERAPEUTICS INC

Ownership history in Commodore Capital LP  ·  9 quarters on record

This page tracks every 13F SEC filing in which Commodore Capital LP reported a position in PROTAGONIST THERAPEUTICS INC (PTGX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
6.38% (2021 Q4)
Avg. % of fund
3.47%
First filed
2020 Q4
Last filed
2025 Q4
Quarters held
9
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 450,000 -575,000 -56.1% 2.62% $39.3M $87.34
2025 Q3 REDUCED 1,025,000 -50,000 -4.7% 3.32% $68.1M $66.43
2025 Q2 ADDED 1,075,000 +743,114 +223.9% 4.19% $59.4M $55.27
2022 Q1 REDUCED 331,886 -473,687 -58.8% 1.76% $7.9M $23.68
5 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    PTGX price (monthly, adj. close)
← Back to Commodore Capital LP Holdings